The Pilot Trap: Why Singapore health startups get stuck after the first hospital win?
Getting your first Singapore hospital pilot can feel like the breakthrough.
Months of meetings. Multiple reviews. Clinical discussions. Product customisation. Procurement conversations.
Then finally: “Yes, let’s pilot it.”
The team celebrates. Investors hear “hospital partnership.” The logo appears on the pitch deck.
And 12 months later? The startup is still piloting.
That is the uncomfortable reality healthtech founders need to confront: a successful pilot is not the same thing as commercial traction.
Executive summary
Singapore is exceptionally good at creating environments where healthcare innovation can be tested... but testing and scaling are two different disciplines.
The companies that escape “pilot purgatory” build evidence for the people who will approve adoption, not only the clinicians who like the product.
And that means designing the commercial pathway before the pilot begins.
The better your pilot goes, the easier it can be to assume the hard part is over.
It isn’t.
In May 2025, NUS Medicine’s Digital Advanced Technology Accelerator convened founders and investors specifically around the problem of moving from healthcare pilots to sustainable revenue.
One issue stood out: healthcare adoption involves multiple stakeholders like clinicians, administrators, procurement teams and IT... and they do not necessarily define “success” the same way.That distinction matters.
Your clinical champion may love the solution because it improves workflow.
IT may see another integration burden.
Procurement may ask whether the economics justify replacing an existing process.
Management may ask whether the result can be replicated across multiple sites.
The pilot can therefore be clinically successful and commercially unsuccessful at exactly the same time.
And Singapore’s healthcare ecosystem increasingly recognises this gap.
CHISEL, the Centre for Healthcare Innovation Start-Up Enterprise Link, explicitly focuses on moving market-ready innovations from proof-of-value towards adoption and procurement.
Across five runs from 2021 to 2025, more than 1,800 innovators from 88 countries competed, with 18 companies receiving around S$9.5 million to test-bed solutions with Singapore healthcare clusters.
Temasek Foundation also reports that Healthcare InnoMatch pilots have impacted more than 1,600 lives, with the potential to reach up to 1.2 million if scaled.
Notice the important words: “If scaled.”
That is where the real game begins.
Singapore’s National Health Innovation Centre is now even more explicit. Its Innovation to Adopt programme considers whether an innovation can be implemented across at least three sites and another healthcare cluster, alongside regulatory readiness and an industry partner’s commitment towards eventual cross-cluster adoption.
In other words, the market is signalling something important to founders: Stop treating the pilot as the destination.Treat it as the evidence engine for scale.
The Execution Playbook
1. Design backwards from procurement
Before agreeing on pilot KPIs, ask a different question:
What evidence would make the next buyer comfortable saying yes?
Not just: “Did clinicians like it?”
Instead:
Did it reduce time?
Did it improve capacity?
Did it reduce administrative workload?
Did it improve a measurable clinical or operational outcome?
What did implementation cost?
What resources would deployment across five sites require?
A pilot designed only to demonstrate that the technology works produces an interesting case study.
A pilot designed around clinical + operational + economic proof produces a sales asset.
That difference is enormous.
2. Build the buying coalition early
One enthusiastic clinician can open the hospital door. They usually cannot scale the contract alone.
Map the stakeholders before the pilot starts:
Clinical champion
Operations
IT / cybersecurity / data
Procurement
Finance
Innovation or transformation leadership
Executive sponsor
Then understand what success means to each. Your marketing also needs to reflect this.
Stop producing one generic “hospital case study.” Build different proof narratives from the same implementation.
Clinical teams need outcomes.
Operations needs workflow impact.
Leadership needs strategic value.
Procurement needs commercial justification.
Same product. Different reasons to buy.
3. Turn the first hospital into a repeatable market story
The first hospital should not become a custom project you spend two years servicing. It should become your blueprint.
Document what had to happen:
What integration was required?
Where did implementation stall?
Which objection appeared repeatedly?
Which metric ultimately mattered?
Which stakeholder accelerated the decision?
Then package those lessons into a repeatable commercial story. This becomes particularly important beyond Singapore.
APAC medtech demand is projected to reach US$132 billion by 2030, growing at 6.9% annually, according to a 2026 Bain report highlighted by Singapore EDB. Yet the same analysis points to structural gaps that prevent promising APAC companies from achieving commercial scale.
So the opportunity is not small. But neither is the execution challenge.
Singapore can give a healthtech company something incredibly valuable: credibility, sophisticated clinical partners and a demanding environment in which to prove value.
But a hospital logo is not a go-to-market strategy.
The smartest founders should not ask: “How do we win another pilot?”
They should ask:
“What must this pilot prove so the next hospital doesn’t need to take the same leap of faith?”That is how a pilot becomes proof. Proof becomes procurement. And procurement becomes scale.
If your healthtech company has a strong Singapore pilot but the commercial story is still struggling to travel across hospitals or APAC markets, that is often a positioning and go-to-market problem... not a product problem.
Comments